INSIDER
01Overview02Daily Brief03Live04Congress05Corporate Insiders06Government Money07Political Influence08Institutions09Washington Network10Follow the Power11Disclosure Clock12AI Investigator13Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenMethodologyMatch reviewLaunch readiness
01Overview02Daily Brief03Live04Congress05Corporate Insiders06Government Money07Political Influence08Institutions09Washington Network10Follow the Power11Disclosure Clock12AI Investigator13Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenMethodologyMatch reviewLaunch readiness
OverviewDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 42h ago
HOUSE PTR2h ago
SEC 13F2h ago
ROBINHOOD CHAIN2h ago
HOUSE PTR/SaleVerified data

Carol D. Miller sold DGX

Self · QUEST DIAGNOSTICS INC · 2000134517 SP Quest Diagnostics Incorporated Common Stock

Side
SELL
Value range
$15K – $50K
Shares
Not disclosed
Price
—
Executed
Mar 10, 2025
Disclosed
Aug 13, 2026
Disclosure timeline521 days from execution to publication · legal deadline 45 days
Mar 10 executedAug 13, 2026 disclosed

DGX · daily

Yahoo Finance chart API
▲Execution▼Disclosure●Material company filing●Other disclosed buy●Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.

Insider Score

Experimental signal
39/ 100 · ELEVATED
Methodology →
  • Transaction type+10 / 20

    Sale

  • Relative size+6 / 25

    Disclosed range starting at $15K

  • Filing timing+15 / 15

    Disclosed 521 days after execution (STOCK Act deadline: 45)

  • Historical behavior+8 / 15

    First recorded trade by this actor in this security

  • Frequency & clustering0 / 15

    No clustered activity in the dataset

  • Market events0 / 10

    No material company filing within 60 days after the trade

    • The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.

    Other disclosed activity · DGX

    ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
    35
    Julie JohnsonDJoint
    DGXQUEST DIAGNOSTICS INC
    Sale
    		SELL$1,001 – $15KOct 30, 2025Aug 5, 2026
    traded Oct 30, 2025
    		+279dHOUSE PTR

    Evidence

    39
    Julie JohnsonDJoint
    DGXQUEST DIAGNOSTICS INC
    Purchase
    		BUY$1,001 – $15KOct 30, 2025Aug 5, 2026
    traded Oct 30, 2025
    		+279dHOUSE PTR

    Evidence

    9
    KK
    Kuppusamy KarthikSVP, Clinical Solutions
    DGXQUEST DIAGNOSTICS INC
    Grant or award
    		A—
    9,853 sh
    		Feb 18, 2026Feb 20, 2026
    traded Feb 18, 2026
    		+2dSEC FORM 4

    Evidence

    5
    DE
    Delaney Mark ESVP & Chief Commercial Officer
    DGXQUEST DIAGNOSTICS INC
    Grant or award
    		A—
    7,332 sh
    		Feb 18, 2026Feb 20, 2026
    traded Feb 18, 2026
    		+2dSEC FORM 4

    Evidence

    12
    KK
    Kuppusamy KarthikSVP, Clinical Solutions
    DGXQUEST DIAGNOSTICS INC
    Tax withholding
    		F$53K
    252 sh
    		Feb 18, 2026Feb 20, 2026
    traded Feb 18, 2026
    		+2dSEC FORM 4

    Evidence

    12
    KK
    Kuppusamy KarthikSVP, Clinical Solutions
    DGXQUEST DIAGNOSTICS INC
    Tax withholding
    		F$54K
    259 sh
    		Feb 18, 2026Feb 20, 2026
    traded Feb 18, 2026
    		+2dSEC FORM 4

    Evidence

    17
    KK
    Kuppusamy KarthikSVP, Clinical Solutions
    DGXQUEST DIAGNOSTICS INC
    Grant or award
    		A—
    2,135 sh
    		Feb 18, 2026Feb 20, 2026
    traded Feb 18, 2026
    		+2dSEC FORM 4

    Evidence

    19
    KK
    Kuppusamy KarthikSVP, Clinical Solutions
    DGXQUEST DIAGNOSTICS INC
    Small acquisition
    		L$2,936
    16 sh
    		Jan 28, 2026Feb 20, 2026
    traded Jan 28, 2026
    		+23dSEC FORM 4

    Evidence

    13
    DE
    Delaney Mark ESVP & Chief Commercial Officer
    DGXQUEST DIAGNOSTICS INC
    Grant or award
    		A—
    1,586 sh
    		Feb 18, 2026Feb 20, 2026
    traded Feb 18, 2026
    		+2dSEC FORM 4

    Evidence

    5
    DE
    Delaney Mark ESVP & Chief Commercial Officer
    DGXQUEST DIAGNOSTICS INC
    Tax withholding
    		F$43K
    205 sh
    		Feb 18, 2026Feb 20, 2026
    traded Feb 18, 2026
    		+2dSEC FORM 4

    Evidence

    5
    DE
    Delaney Mark ESVP & Chief Commercial Officer
    DGXQUEST DIAGNOSTICS INC
    Tax withholding
    		F$48K
    230 sh
    		Feb 18, 2026Feb 20, 2026
    traded Feb 18, 2026
    		+2dSEC FORM 4

    Evidence

    15
    DE
    Delaney Mark ESVP & Chief Commercial Officer
    DGXQUEST DIAGNOSTICS INC
    Small acquisition
    		L$2,753
    15 sh
    		Jan 28, 2026Feb 20, 2026
    traded Jan 28, 2026
    		+23dSEC FORM 4

    Evidence

    8
    DE
    Delaney Mark ESVP & Chief Commercial Officer
    DGXQUEST DIAGNOSTICS INC
    Option exercise · 10b5-1 plan
    		M$1.13M
    7,846 sh
    		Nov 18, 2025Nov 20, 2025
    traded Nov 18, 2025
    		+2dSEC FORM 4

    Evidence

    0
    DE
    Delaney Mark ESVP & Chief Commercial Officer
    DGXQUEST DIAGNOSTICS INC
    Option exercise · 10b5-1 plan
    		M$14K
    100 sh
    		Nov 18, 2025Nov 20, 2025
    traded Nov 18, 2025
    		+2dSEC FORM 4

    Evidence

    26
    DE
    Delaney Mark ESVP & Chief Commercial Officer
    DGXQUEST DIAGNOSTICS INC
    Open-market sale · 10b5-1 plan
    		SELL$1.49M
    7,946 sh
    		Nov 18, 2025Nov 20, 2025
    traded Nov 18, 2025
    		+2dSEC FORM 4

    Evidence

    0
    DE
    Delaney Mark ESVP & Chief Commercial Officer
    DGXQUEST DIAGNOSTICS INC
    Option exercise · 10b5-1 plan
    		M$14K
    100 sh
    		Nov 18, 2025Nov 20, 2025
    traded Nov 18, 2025
    		+2dSEC FORM 4

    Evidence

    20
    DE
    Delaney Mark ESVP & Chief Commercial Officer
    DGXQUEST DIAGNOSTICS INC
    Option exercise · 10b5-1 plan
    		M$1.13M
    7,846 sh
    		Nov 18, 2025Nov 20, 2025
    traded Nov 18, 2025
    		+2dSEC FORM 4

    Evidence

    Evidence

    Verified data

    Read directly from the primary public document; every field below is as reported by the filer.

    Source

    Document
    House Periodic Transaction Report
    Publisher
    Clerk of the U.S. House of Representatives
    Document ID
    20033779

    Timestamps

    Event (reported)
    Mar 10, 2025
    Published
    Aug 13, 2026
    Ingested by INSIDER
    Nov 5, 00:34 UTC
    Last re-read
    Nov 5, 06:47 UTC

    Extracted facts

    Filer
    Carol D. Miller
    Role
    Self
    Transaction
    SaleAs filed: “S”
    Asset
    2000134517 SP Quest Diagnostics Incorporated Common Stock
    Ticker
    DGX
    Reported value
    $15K – $50KAs filed: “$15,001 - $50,000”
    Execution date (reported)
    Mar 10, 2025
    Notification date (reported)
    Apr 11, 2025
    Days from execution to publication
    521

    Calculation

    Midpoint = (low + high) / 2. Used only to rank and sum ranges; the true value can be anywhere in the range.

    • Low: $15,001
    • High: $50,000

    = $32,501

    What this establishes

    Carol D. Miller reported a sale of 2000134517 SP Quest Diagnostics Incorporated Common Stock. Members report a value range, not an exact amount, and do not report share counts or prices. Dates are as entered by the filer. A trade report is not evidence of wrongdoing.

    Extraction

    Method
    PDF text extraction
    Confidence
    1.00
    Self
    Carol D. Millerbioguide:M001205
    Issuer
    QUEST DIAGNOSTICS INCcik:0001022079

    Revision history · 0

    No field has changed since this record was first ingested.

    Company events

    No records

    No material filings recorded for this issuer.